Search results
Results from the WOW.Com Content Network
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical substance or an active ingredient, [1] encompassing compounds, peptides and low-molecular-weight proteins (e.g., insulin, hormones, cytokines), as well as complex biological products, such as those used for gene therapy. [2]
Neluxicapone (INN Tooltip International Nonproprietary Name) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024. [1] [2] [3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), also known as O-methylbufotenin or mebufotenin (INN Tooltip International Nonproprietary Name), is a naturally occurring psychedelic of the tryptamine family. [5] [1] [4] [2] It is found in a wide variety of plant species, and is also secreted by the glands of at least one toad species, the Colorado ...
Search. Appearance. ... Serplulimab is the International nonproprietary name. [6 ... "First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a ...
Relugolix is the generic name of the drug and its INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name, and JAN Tooltip Japanese Accepted Name. [19] [20] It is also known by its former developmental code names RVT-601 and TAK-385. [12] [19]
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
A Japanese Accepted Name (Japanese: 日本医薬品一般的名称, Hepburn: Nihon Iyakuhin Ippan-teki Meishō) (JAN) is the official non-proprietary or generic name given to a pharmaceutical substance by the Government of Japan.
Its original recommended International nonproprietary name (rINN) was tasocitinib, [32] but that was overruled during the INN approval process as being not optimally differentiable from other existing INNs, so the name "tofacitinib" was proposed and became the INN. In November 2012, the FDA approved tofacitinib for treatment of rheumatoid ...